Takeda reports ‘significant milestone’ with diabetes drug submission

Takeda Pharmaceutical has announced a major leap forward for the company with the submission of alogliptin (SYR-322) to regulatory authorities as a treatment for type two diabetes.

Alogliptin has been submitted to the US Food and Drug Administration by the Takeda Global Research & Development Centre.

The compound is a highly-selective dipeptidyl peptidase-IV (DPP-4) inhibitor originally discovered by Takeda San Diego and deigned to be administered orally once a day.

A new class of treatment for type two diabetes, DPP-4 inhibitors slow down the inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic peptide that play a key role in the regulation of blood glucose.

Yasuchika Hasegawa, president of Takeda, said: “The new drug application submission for alogliptin is a significant milestone for Takeda, as it has the potential to strengthen Takeda’s position as one of the global leaders in diabetes treatment.”

He added that the companies continued growth is dependent on its success in this therapeutic field, with the firm hoping that the drug becomes an important treatment option for patients with type two diabetes.

In July 2007, Takeda reported that the development of angiotensin receptor blocker TAK-491 will boost its profile in diabetes, metabolic conditions and hypertension.